Multicenter trial of naloxone in alzheimer's disease

V. W. Henderson, E. Roberts, C. Wimer, E. L. Bardolph, H. C. Chui, A. R. Damasio, P. J. Eslinger, M. F. Folstein, L. S. Schneider, E. L. Teng, L. E. Tune, L. P. Weiner, P. J. Whitehouse

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

In a double‐blind, placebo‐controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1‐mg or 10‐mg doses; 15 patients at 1 center were similarly unimproved after receiving 30 mg naloxone (single blind). Findings fail to support claims that naloxone monotherapy ameliorates cognitive impairments of Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)404-406
Number of pages3
JournalAnnals of Neurology
Volume25
Issue number4
DOIs
StatePublished - Apr 1989

Fingerprint

Naloxone
Multicenter Studies
Alzheimer Disease
Cross-Over Studies

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Henderson, V. W., Roberts, E., Wimer, C., Bardolph, E. L., Chui, H. C., Damasio, A. R., ... Whitehouse, P. J. (1989). Multicenter trial of naloxone in alzheimer's disease. Annals of Neurology, 25(4), 404-406. https://doi.org/10.1002/ana.410250413
Henderson, V. W. ; Roberts, E. ; Wimer, C. ; Bardolph, E. L. ; Chui, H. C. ; Damasio, A. R. ; Eslinger, P. J. ; Folstein, M. F. ; Schneider, L. S. ; Teng, E. L. ; Tune, L. E. ; Weiner, L. P. ; Whitehouse, P. J. / Multicenter trial of naloxone in alzheimer's disease. In: Annals of Neurology. 1989 ; Vol. 25, No. 4. pp. 404-406.
@article{1e7230528ec3491480c2be24eca78c48,
title = "Multicenter trial of naloxone in alzheimer's disease",
abstract = "In a double‐blind, placebo‐controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1‐mg or 10‐mg doses; 15 patients at 1 center were similarly unimproved after receiving 30 mg naloxone (single blind). Findings fail to support claims that naloxone monotherapy ameliorates cognitive impairments of Alzheimer's disease.",
author = "Henderson, {V. W.} and E. Roberts and C. Wimer and Bardolph, {E. L.} and Chui, {H. C.} and Damasio, {A. R.} and Eslinger, {P. J.} and Folstein, {M. F.} and Schneider, {L. S.} and Teng, {E. L.} and Tune, {L. E.} and Weiner, {L. P.} and Whitehouse, {P. J.}",
year = "1989",
month = "4",
doi = "10.1002/ana.410250413",
language = "English (US)",
volume = "25",
pages = "404--406",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

Henderson, VW, Roberts, E, Wimer, C, Bardolph, EL, Chui, HC, Damasio, AR, Eslinger, PJ, Folstein, MF, Schneider, LS, Teng, EL, Tune, LE, Weiner, LP & Whitehouse, PJ 1989, 'Multicenter trial of naloxone in alzheimer's disease', Annals of Neurology, vol. 25, no. 4, pp. 404-406. https://doi.org/10.1002/ana.410250413

Multicenter trial of naloxone in alzheimer's disease. / Henderson, V. W.; Roberts, E.; Wimer, C.; Bardolph, E. L.; Chui, H. C.; Damasio, A. R.; Eslinger, P. J.; Folstein, M. F.; Schneider, L. S.; Teng, E. L.; Tune, L. E.; Weiner, L. P.; Whitehouse, P. J.

In: Annals of Neurology, Vol. 25, No. 4, 04.1989, p. 404-406.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Multicenter trial of naloxone in alzheimer's disease

AU - Henderson, V. W.

AU - Roberts, E.

AU - Wimer, C.

AU - Bardolph, E. L.

AU - Chui, H. C.

AU - Damasio, A. R.

AU - Eslinger, P. J.

AU - Folstein, M. F.

AU - Schneider, L. S.

AU - Teng, E. L.

AU - Tune, L. E.

AU - Weiner, L. P.

AU - Whitehouse, P. J.

PY - 1989/4

Y1 - 1989/4

N2 - In a double‐blind, placebo‐controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1‐mg or 10‐mg doses; 15 patients at 1 center were similarly unimproved after receiving 30 mg naloxone (single blind). Findings fail to support claims that naloxone monotherapy ameliorates cognitive impairments of Alzheimer's disease.

AB - In a double‐blind, placebo‐controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1‐mg or 10‐mg doses; 15 patients at 1 center were similarly unimproved after receiving 30 mg naloxone (single blind). Findings fail to support claims that naloxone monotherapy ameliorates cognitive impairments of Alzheimer's disease.

UR - http://www.scopus.com/inward/record.url?scp=0024523689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024523689&partnerID=8YFLogxK

U2 - 10.1002/ana.410250413

DO - 10.1002/ana.410250413

M3 - Article

C2 - 2653175

AN - SCOPUS:0024523689

VL - 25

SP - 404

EP - 406

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 4

ER -

Henderson VW, Roberts E, Wimer C, Bardolph EL, Chui HC, Damasio AR et al. Multicenter trial of naloxone in alzheimer's disease. Annals of Neurology. 1989 Apr;25(4):404-406. https://doi.org/10.1002/ana.410250413